Wells Fargo & Company Scynexis Inc Transaction History
Wells Fargo & Company
- $468 Billion
- Q2 2025
A detailed history of Wells Fargo & Company transactions in Scynexis Inc stock. As of the latest transaction made, Wells Fargo & Company holds 6,770 shares of SCYX stock, worth $5,348. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,770
Previous 6,110
10.8%
Holding current value
$5,348
Previous $5,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding SCYX
# of Institutions
45Shares Held
11.8MCall Options Held
0Put Options Held
0-
Federated Hermes, Inc. Pittsburgh, PA2.9MShares$2.29 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$1.77 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.66MShares$1.31 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.23MShares$970,8380.22% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC556KShares$438,8880.7% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $25.8M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...